CN114099936A - 一种长效美容填充和缓释给药用可溶微针及其制备方法 - Google Patents
一种长效美容填充和缓释给药用可溶微针及其制备方法 Download PDFInfo
- Publication number
- CN114099936A CN114099936A CN202111302340.6A CN202111302340A CN114099936A CN 114099936 A CN114099936 A CN 114099936A CN 202111302340 A CN202111302340 A CN 202111302340A CN 114099936 A CN114099936 A CN 114099936A
- Authority
- CN
- China
- Prior art keywords
- methacryloylated
- microneedle
- long
- soluble
- cosmetic filling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 238000013268 sustained release Methods 0.000 title claims abstract description 19
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 19
- 239000004005 microsphere Substances 0.000 claims abstract description 32
- 229920000642 polymer Polymers 0.000 claims abstract description 31
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 16
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 16
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 16
- 239000000661 sodium alginate Substances 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 14
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 12
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 12
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 12
- AEMOLEFTQBMNLQ-AZLKCVHYSA-N (2r,3s,4s,5s,6r)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound O[C@@H]1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-AZLKCVHYSA-N 0.000 claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 3
- 239000010410 layer Substances 0.000 claims description 31
- 229940079593 drug Drugs 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 11
- 239000012620 biological material Substances 0.000 claims description 9
- 229920001610 polycaprolactone Polymers 0.000 claims description 9
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 8
- 229920001661 Chitosan Polymers 0.000 claims description 8
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 8
- ISAOCJYIOMOJEB-UHFFFAOYSA-N benzoin Chemical compound C=1C=CC=CC=1C(O)C(=O)C1=CC=CC=C1 ISAOCJYIOMOJEB-UHFFFAOYSA-N 0.000 claims description 8
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 8
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 6
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims description 5
- 229920001432 poly(L-lactide) Polymers 0.000 claims description 5
- 239000000758 substrate Substances 0.000 claims description 5
- 239000002344 surface layer Substances 0.000 claims description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
- 102000012422 Collagen Type I Human genes 0.000 claims description 4
- 108010022452 Collagen Type I Proteins 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 4
- 102000016942 Elastin Human genes 0.000 claims description 4
- 108010014258 Elastin Proteins 0.000 claims description 4
- 108010022355 Fibroins Proteins 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 244000028419 Styrax benzoin Species 0.000 claims description 4
- 235000000126 Styrax benzoin Nutrition 0.000 claims description 4
- 235000008411 Sumatra benzointree Nutrition 0.000 claims description 4
- 150000008062 acetophenones Chemical class 0.000 claims description 4
- -1 aromatic ketone compounds Chemical class 0.000 claims description 4
- 229960002130 benzoin Drugs 0.000 claims description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 4
- 229920002549 elastin Polymers 0.000 claims description 4
- 239000012949 free radical photoinitiator Substances 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 235000019382 gum benzoic Nutrition 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims description 4
- 239000004632 polycaprolactone Substances 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 102000004877 Insulin Human genes 0.000 claims description 3
- 108090001061 Insulin Proteins 0.000 claims description 3
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 claims description 3
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 3
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 3
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 229960001338 colchicine Drugs 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- HCIBTBXNLVOFER-UHFFFAOYSA-N diphenylcyclopropenone Chemical compound O=C1C(C=2C=CC=CC=2)=C1C1=CC=CC=C1 HCIBTBXNLVOFER-UHFFFAOYSA-N 0.000 claims description 3
- 229960002311 dithranol Drugs 0.000 claims description 3
- 229940042370 ethinyl estradiol / norgestimate Drugs 0.000 claims description 3
- 239000003862 glucocorticoid Substances 0.000 claims description 3
- 229940125396 insulin Drugs 0.000 claims description 3
- 229960003632 minoxidil Drugs 0.000 claims description 3
- 229960001319 parathyroid hormone Drugs 0.000 claims description 3
- 239000000199 parathyroid hormone Substances 0.000 claims description 3
- 238000005086 pumping Methods 0.000 claims description 3
- 229940037128 systemic glucocorticoids Drugs 0.000 claims description 3
- 229960002117 triamcinolone acetonide Drugs 0.000 claims description 3
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 3
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 claims description 3
- 229960001360 zolmitriptan Drugs 0.000 claims description 3
- TWYFGYXQSYOKLK-CYUSMAIQSA-N varenicline tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 TWYFGYXQSYOKLK-CYUSMAIQSA-N 0.000 claims description 2
- 229960003977 varenicline tartrate Drugs 0.000 claims description 2
- 230000005923 long-lasting effect Effects 0.000 claims 2
- 229960004748 abacavir Drugs 0.000 claims 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 7
- 239000000945 filler Substances 0.000 abstract description 5
- 102000008186 Collagen Human genes 0.000 abstract description 2
- 108010035532 Collagen Proteins 0.000 abstract description 2
- 229920001436 collagen Polymers 0.000 abstract description 2
- 206010020718 hyperplasia Diseases 0.000 abstract description 2
- 230000000472 traumatic effect Effects 0.000 abstract description 2
- 230000037303 wrinkles Effects 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 32
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 230000001678 irradiating effect Effects 0.000 description 3
- 125000005395 methacrylic acid group Chemical group 0.000 description 3
- 150000008365 aromatic ketones Chemical class 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 239000003509 long acting drug Substances 0.000 description 1
- 239000011806 microball Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- LLYYNOVSVPBRGV-MVNKZKPCSA-N valnemulin Chemical compound CC(C)[C@@H](N)C(=O)NCC(C)(C)SCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@@]23CC[C@@H](C)[C@]1(C)[C@@H]2C(=O)CC3 LLYYNOVSVPBRGV-MVNKZKPCSA-N 0.000 description 1
- 229950008166 valnemulin Drugs 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0204—Specific forms not provided for by any of groups A61K8/0208 - A61K8/14
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/733—Alginic acid; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0046—Solid microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0053—Methods for producing microneedles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Birds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明提供一种长效美容填充和缓释给药用可溶微针及其制备方法,其针体采用高分子微球与低分子量的透明质酸钠或高α‑L‑古洛糖醛酸含量的海藻酸钠中的任意一种或者两者混合制成,同时高分子微球也可以复合药物。所制备的微针直径小,扎入皮内无痛、不出血、无创伤,故消费者自行即可将微针贴贴敷于需填充部位,待微针针体成分在皮内溶解后,即可释放出包裹的高分子填充物微球。高分子微球在皮内可保持数月至数年的时间才能逐渐降解,在此过程中,先会起到一些即时填充效果,然后降解、被皮肤所吸收,进而刺激、诱导皮肤胶原蛋白增生,达到紧致、提升、增加弹性、改善皱纹的效果,从而起到长效的美容填充的效果。而且采用两步法,大大提高了生产效率。
Description
技术领域
本发明涉及微针贴制备领域,具体涉及一种快速高效制备微针贴的方法。
背景技术
传统的美容填充剂多为交联凝胶型的填充物(如交联HA,交联的PCL、 PLLA等),需要通过注射器向皮内或皮下注射,需要到专业的医疗机构进行注射。使用起来比较麻烦,需要先进行局部麻醉,再经专业的医师进行有创注射,注射后还需进行数日的伤口修复和护理,存在感染风险和结痂风险。同时注射物有堵塞局部毛细血管的可能,尤其是眼周毛细血管,造成被注射者失明,此现象在美容注射填充领域时有发生。
发明内容
本发明旨在提供一种长效美容填充和缓释给药用可溶微针及其制备方法,其目的是解决现有的技术缺陷,其采用的技术方案是:
一种长效美容填充和缓释给药用可溶微针,其针体采用高分子微球与低分子量的透明质酸钠或高α-L-古洛糖醛酸含量的海藻酸钠中的任意一种或者两者混合制成。
优选的,所述的高分子微球直径大小10~60微米,其成分包括但不限于PCL,PLLA。
优选的,所述的高分子微球为包裹药物分子或不包裹药物分子的任意一种。
优选的,所述的药物分子包括不限于胰岛素、秋水仙碱、佐米曲坦、米诺地尔、蒽林、二苯环丙烯酮、糖皮质激素类、曲安奈德,阿巴拉特、甲状旁腺素、复方炔雌醇/诺孕曲明、酒石酸伐尼克兰、海姆泊芬中的一种或者任意几种。
优选的,所述的长效美容填充和缓释给药用可溶微针的制备方法,第一步为制作微针针体部分,将高分子微球均匀分散于微针针体溶液中,将所述微针针体溶液注入微针模具中,去除表层多余溶液,干燥,即得无基底层的微针阵列;第二步为制作微针的基底层,将基底层制备溶液倒入含有固化的微针阵列的模具中,所述的基底层制备溶液厚度为0.5mm~5mm,离心或者抽真空后,使基底层固化成膜,干燥后可得长效美容填充和缓释给药用可溶微针。
优选的,所述的微针针体溶液由低分子量的透明质酸钠或高α-L-古洛糖醛酸含量的海藻酸钠中的任意一种或者两者混合制成。
优选的,所述的低分子量的透明质酸钠的分子量为1000~50000Da,所述的高G(α-L-古洛糖醛酸)含量的海藻酸钠中G:M>1.2:1。
优选的,所述的基底层制备溶液用甲基丙烯酰化的光敏型生物材料制备为浓度为2%~30%溶液,同时添加0.3%~6%w/w的光敏引发剂。
优选的,所述的甲基丙烯酰化的光敏型生物材料选用但不限于甲基丙烯酰化聚乙烯醇、甲基丙烯酰化明胶、甲基丙烯酰化透明质酸、甲基丙烯酰化硫酸软骨素、甲基丙烯酰化海藻酸纳、甲基丙烯酰化羧甲基壳聚糖、甲基丙烯酰化丝素蛋白、甲基丙烯酰化Ⅰ型胶原、甲基丙烯酰化弹性蛋白、甲基丙烯酰化硫酸软骨素、甲基丙烯酰化壳聚糖、甲基丙烯酰化葡聚糖、甲基丙烯酰化聚已内酯中的一种或多种。
优选的,所述的光敏引发剂包括但不限于离子型光敏引发剂、自由基型光敏引发剂。
优选的,所述的光敏引发剂为安息香及其衍生物,苯乙酮衍生物,芳香酮类化合物中的一种或者多种。
优选的,所述的基底层制备时,基底层溶液厚度为0.5mm~5mm,离心或者抽真空后,分别在250nm~420 nm紫外光照射下数秒至数分钟,使基底层迅速固化成膜,然后经约3min~30min的干燥,即可脱模制得针体强度高的长效美容填充和缓释给药用可溶微针。
本发明用交联的、生物相容性好的高分子材料,制备成纳米微球,然后复合在可溶性微针内。由于微针尺寸较小,扎入皮内无痛、不出血、无创伤,故消费者自行即可将微针贴贴敷于需填充部位,待微针针体成分在皮内溶解后,即可释放出包裹的高分子填充物微球。高分子微球在皮内可保持数月至数年的时间才能逐渐降解,在此过程中,先会起到一些即时填充效果,然后降解、被皮肤所吸收,进而刺激、诱导皮肤胶原蛋白增生,达到紧致、提升、增加弹性、改善皱纹的效果,从而起到长效的美容填充的效果。同时,由于可溶微针尺寸小的特点,仅刺到真皮层中部,不会伤及血管和神经,因此无痛,且没有堵塞毛细血管的风险,是一种具有安全、高效、使用方便、长效等优点的美容填充物,与传统注射相比,具有十分明显的优势,有着广泛的应用前景。
此外,本发明,也可应用于皮内缓释给药。将具有止痛功效的药物分子、降血糖用的药物分子、避孕用的药物分子等包裹于高分子微球内,高分子微针均匀分散于微针制备液中,通过干燥成型、形成含有高分子微球的可溶微针贴。高分子微球通过缓慢降解,逐步释放所包裹的药物分子,起到缓释、长效给药的目的。大大提高患者用药的便利性、降低用药次数等。
附图说明
图1为制备的长效美容填充和缓释给药用可溶微针。
具体实施方式
以下结合具体实施例对本发明的技术方案作进一步详细的描述,但本发明的保护范围及实施方式不限于此。本发明可以以许多不同的形式来实现,并不限于本文所描述的实施例。
实施例 1
使用两步法,制备含有低分子量的透明质酸钠的长效美容填充和缓释给药用可溶微针
选用的高分子微球的直径为10~60微米,其成分为PCL,其内包含药物成分为胰岛素、秋水仙碱、佐米曲坦、米诺地尔、蒽林、二苯环丙烯酮、糖皮质激素类、曲安奈德,阿巴拉特、甲状旁腺素、复方炔雌醇/诺孕曲明、酒石酸伐尼克兰、海姆泊芬中的一种或者任意几种。
选用的低分子量的透明质酸钠低分子量为1000~50000Da。
基底层制备溶液用甲基丙烯酰化的光敏型生物材料制备成浓度为2%~30%溶液,同时添加0.3%~6%w/w的光敏引发剂,混合均匀。
第一步:制作微针针体部分,将高分子微球均匀分散于含有低分子量的透明质酸钠的微针针体溶液中,然后注入微针模具中,去除表层多余溶液,干燥,即得无基底层的微针阵列。
第二步:制作微针的基底层,将基底层制备溶液倒入含有固化的微针阵列的模具中,控制溶液厚度为0.5mm~5mm,离心或者抽真空后,分别在250nm~420 nm紫外光照射下数秒至数分钟,使基底层迅速固化成膜,然后经约3min~30min的干燥,即可脱模制得针体强度高的长效美容填充和缓释给药用可溶微针。
实施例2
使用两步法,制备含有高α-L-古洛糖醛酸含量的海藻酸钠的长效美容填充和缓释给药用可溶微针
选用的高分子微球的直径为10~60微米,其成分为PLLA,其不含含药物成分。
选用的高G(α-L-古洛糖醛酸)含量的海藻酸钠中G:M>1.2:1。
基底层制备溶液用甲基丙烯酰化的光敏型生物材料制备成浓度为2%~30%溶液,同时添加0.3%~6%w/w的光敏引发剂,混合均匀。
甲基丙烯酰化的光敏型生物材料选用但不限于甲基丙烯酰化聚乙烯醇、甲基丙烯酰化明胶、甲基丙烯酰化透明质酸、甲基丙烯酰化硫酸软骨素、甲基丙烯酰化海藻酸纳、甲基丙烯酰化羧甲基壳聚糖、甲基丙烯酰化丝素蛋白、甲基丙烯酰化Ⅰ型胶原、甲基丙烯酰化弹性蛋白、甲基丙烯酰化硫酸软骨素、甲基丙烯酰化壳聚糖、甲基丙烯酰化葡聚糖、甲基丙烯酰化聚已内酯中的一种或多种。
光敏引发剂包括但不限于离子型光敏引发剂、自由基型光敏引发剂。如安息香及其衍生物,苯乙酮衍生物,芳香酮类化合物。如TPO光引发剂,TPO-L光引发剂,907光引发剂,ITX光引发剂,EDB光引发剂,184光引发剂,1173光引发剂,BDK光引发剂,OMBB光引发剂,CBP光引发剂等。
第一步:制作微针针体部分,将高分子微球均匀分散于高G(α-L-古洛糖醛酸)含量的海藻酸钠(G:M>1.2:1)微针针体溶液中,然后注入微针模具中,去除表层多余溶液,干燥,即得无基底层的微针阵列。
第二步:制作微针的基底层,将基底层制备溶液倒入含有固化的微针阵列的模具中,控制溶液厚度为0.5mm~5mm,离心或者抽真空后,分别在250nm~420 nm紫外光照射下数秒至数分钟,使基底层迅速固化成膜,然后经约3min~30min的干燥,即可脱模制得针体强度高的长效美容填充和缓释给药用可溶微针。
实施例3
使用两步法,制备含有低分子量的透明质酸钠和高α-L-古洛糖醛酸含量的海藻酸钠的长效美容填充和缓释给药用可溶微针。
选用的高分子微球的直径为10~60微米,其成分为PLC与PLLA混合物,其不含药物成分。
选用的高G(α-L-古洛糖醛酸)含量的海藻酸钠中G:M>1.2:1。
选用的低分子量的透明质酸钠低分子量为1000~50000Da。
针体制备液中高G海藻酸钠含量为3%~20%、低分子量透明质酸钠的含量为5%~16%。
基底层制备溶液用甲基丙烯酰化的光敏型生物材料制备成浓度为2%~30%溶液,同时添加0.3%~6%w/w的光敏引发剂,混合均匀。
甲基丙烯酰化的光敏型生物材料选用但不限于甲基丙烯酰化聚乙烯醇、甲基丙烯酰化明胶、甲基丙烯酰化透明质酸、甲基丙烯酰化硫酸软骨素、甲基丙烯酰化海藻酸纳、甲基丙烯酰化羧甲基壳聚糖、甲基丙烯酰化丝素蛋白、甲基丙烯酰化Ⅰ型胶原、甲基丙烯酰化弹性蛋白、甲基丙烯酰化硫酸软骨素、甲基丙烯酰化壳聚糖、甲基丙烯酰化葡聚糖、甲基丙烯酰化聚已内酯中的一种或多种。
光敏引发剂包括但不限于离子型光敏引发剂、自由基型光敏引发剂。如安息香及其衍生物,苯乙酮衍生物,芳香酮类化合物。如TPO光引发剂,TPO-L光引发剂,907光引发剂,ITX光引发剂,EDB光引发剂,184光引发剂,1173光引发剂,BDK光引发剂,OMBB光引发剂,CBP光引发剂等。
第一步:制作微针针体部分,将高分子微球均匀分散于微针针体溶液中,然后注入微针模具中,去除表层多余溶液,干燥,即得无基底层的微针阵列。
第二步:制作微针的基底层,将基底层制备溶液倒入含有固化的微针阵列的模具中,控制溶液厚度为0.5mm~5mm,离心或者抽真空后,分别在250nm~420 nm紫外光照射下数秒至数分钟,使基底层迅速固化成膜,然后经约3min~30min的干燥,即可脱模制得针体强度高的长效美容填充和缓释给药用可溶微针。
制备的微针如图1所示。
Claims (10)
1.一种长效美容填充和缓释给药用可溶微针,其特征在于:所述的长效美容填充和缓释给药用可溶微针的微针针体含有高分子微球,所述的高分子微球直径大小10~60微米。
2.根据权利要求1所述的一种长效美容填充和缓释给药用可溶微针,其特征在于:所述的高分子微球包括但不限于PCL,PLLA,所述的高分子微球制备可从包裹药物分子或不包裹药物分子中选一。
3.根据权利要求2所述的一种长效美容填充和缓释给药用可溶微针,其特征在于:所述的药物分子包括不限于胰岛素、秋水仙碱、佐米曲坦、米诺地尔、蒽林、二苯环丙烯酮、糖皮质激素类、曲安奈德,阿巴拉特、甲状旁腺素、复方炔雌醇/诺孕曲明、酒石酸伐尼克兰、海姆泊芬中的一种或者任意几种。
4.提供如权利要求1所述的长效美容填充和缓释给药用可溶微针的制备方法,其特征在于:所述的制备方法为分两步制作,第一步为制作微针针体部分,将高分子微球均匀分散于微针针体溶液中,将所述微针针体溶液注入微针模具中,去除表层多余溶液,干燥,即得无基底层的微针阵列;第二步为制作微针的基底层,将基底层制备溶液倒入含有固化的微针阵列的模具中,所述的基底层制备溶液厚度为0.5mm~5mm,离心或者抽真空后,使基底层固化成膜,干燥后可得长效美容填充和缓释给药用可溶微针。
5.根据权利要求4所述的一种长效美容填充和缓释给药用可溶微针的制备方法,其特征在于:所述的微针针体溶液由低分子量的透明质酸钠或高α-L-古洛糖醛酸含量的海藻酸钠中的任意一种或者两者混合制成。
6.根据权利要求5所述的一种长效美容填充和缓释给药用可溶微针的制备方法,其特征在于:所述的低分子量的透明质酸钠的分子量为1000~50000Da,所述的高α-L-古洛糖醛酸含量的海藻酸钠中G:M>1.2:1。
7.根据权利要求5所述的一种长效美容填充和缓释给药用可溶微针的制备方法,其特征在于:所述的基底层制备溶液用甲基丙烯酰化的光敏型生物材料制备为浓度为2%~30%溶液,同时添加0.3%~6%w/w的光敏引发剂。
8.根据权利要求7所述的一种长效美容填充和缓释给药用可溶微针的制备方法,其特征在于:所述的甲基丙烯酰化的光敏型生物材料选用但不限于甲基丙烯酰化聚乙烯醇、甲基丙烯酰化明胶、甲基丙烯酰化透明质酸、甲基丙烯酰化硫酸软骨素、甲基丙烯酰化海藻酸纳、甲基丙烯酰化羧甲基壳聚糖、甲基丙烯酰化丝素蛋白、甲基丙烯酰化Ⅰ型胶原、甲基丙烯酰化弹性蛋白、甲基丙烯酰化硫酸软骨素、甲基丙烯酰化壳聚糖、甲基丙烯酰化葡聚糖、甲基丙烯酰化聚已内酯中的一种或多种。
9.根据权利要求7所述的一种长效美容填充和缓释给药用可溶微针的制备方法,其特征在于:所述的光敏引发剂包括但不限于离子型光敏引发剂、自由基型光敏引发剂。
10.根据权利要求7所述的一种长效美容填充和缓释给药用可溶微针的制备方法,其特征在于:所述的光敏引发剂为安息香及其衍生物,苯乙酮衍生物,芳香酮类化合物中的一种或者多种。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2021112791668 | 2021-10-31 | ||
CN202111279166 | 2021-10-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114099936A true CN114099936A (zh) | 2022-03-01 |
Family
ID=80380649
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111302340.6A Pending CN114099936A (zh) | 2021-10-31 | 2021-11-04 | 一种长效美容填充和缓释给药用可溶微针及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114099936A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114796842A (zh) * | 2022-05-30 | 2022-07-29 | 深圳高性能医疗器械国家研究院有限公司 | 经皮药物导入结构及其制备方法、经皮药物导入系统 |
CN115337530A (zh) * | 2022-09-05 | 2022-11-15 | 安徽中医药大学 | 一种秋水仙碱水凝胶微针及其制备方法 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106063948A (zh) * | 2016-03-30 | 2016-11-02 | 圆容生物医药无锡有限公司 | 一种长效皮下植入物及其制备方法 |
KR20170123099A (ko) * | 2016-04-28 | 2017-11-07 | 주식회사 한국비엔씨 | 폴리카프로락톤 및 히알루론산을 포함하는 피부용 필러 조성물 |
CN109621181A (zh) * | 2018-11-02 | 2019-04-16 | 华南理工大学 | 一种光热响应性复合微针及其制备方法 |
CN109998997A (zh) * | 2019-04-04 | 2019-07-12 | 山东谷雨春生物科技有限公司 | 一种利用膜乳化法制备聚酯类有机高分子微球的方法 |
CN110302172A (zh) * | 2019-07-18 | 2019-10-08 | 广东省医疗器械研究所 | 一种聚合物复合微球、其制备方法及应用 |
CN111184909A (zh) * | 2019-10-21 | 2020-05-22 | 湖北翎美生物科技有限公司 | 一种透明质酸缓释填充物及制备方法 |
CN111375124A (zh) * | 2020-03-19 | 2020-07-07 | 上海缓释新材料科技有限公司 | 基于聚乳酸类化合物的抗衰老缓释可溶微针及其制备方法 |
CN112451470A (zh) * | 2020-12-28 | 2021-03-09 | 南京鼓楼医院 | 一种均匀给药的载药微球-微针阵列、制备方法及应用 |
CN113559251A (zh) * | 2021-06-21 | 2021-10-29 | 北京航空航天大学 | 可溶性微针贴片及其制备方法和用途 |
-
2021
- 2021-11-04 CN CN202111302340.6A patent/CN114099936A/zh active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106063948A (zh) * | 2016-03-30 | 2016-11-02 | 圆容生物医药无锡有限公司 | 一种长效皮下植入物及其制备方法 |
KR20170123099A (ko) * | 2016-04-28 | 2017-11-07 | 주식회사 한국비엔씨 | 폴리카프로락톤 및 히알루론산을 포함하는 피부용 필러 조성물 |
CN109621181A (zh) * | 2018-11-02 | 2019-04-16 | 华南理工大学 | 一种光热响应性复合微针及其制备方法 |
CN109998997A (zh) * | 2019-04-04 | 2019-07-12 | 山东谷雨春生物科技有限公司 | 一种利用膜乳化法制备聚酯类有机高分子微球的方法 |
CN110302172A (zh) * | 2019-07-18 | 2019-10-08 | 广东省医疗器械研究所 | 一种聚合物复合微球、其制备方法及应用 |
CN111184909A (zh) * | 2019-10-21 | 2020-05-22 | 湖北翎美生物科技有限公司 | 一种透明质酸缓释填充物及制备方法 |
CN111375124A (zh) * | 2020-03-19 | 2020-07-07 | 上海缓释新材料科技有限公司 | 基于聚乳酸类化合物的抗衰老缓释可溶微针及其制备方法 |
CN112451470A (zh) * | 2020-12-28 | 2021-03-09 | 南京鼓楼医院 | 一种均匀给药的载药微球-微针阵列、制备方法及应用 |
CN113559251A (zh) * | 2021-06-21 | 2021-10-29 | 北京航空航天大学 | 可溶性微针贴片及其制备方法和用途 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114796842A (zh) * | 2022-05-30 | 2022-07-29 | 深圳高性能医疗器械国家研究院有限公司 | 经皮药物导入结构及其制备方法、经皮药物导入系统 |
CN114796842B (zh) * | 2022-05-30 | 2024-03-29 | 深圳高性能医疗器械国家研究院有限公司 | 经皮药物导入结构及其制备方法、经皮药物导入系统 |
CN115337530A (zh) * | 2022-09-05 | 2022-11-15 | 安徽中医药大学 | 一种秋水仙碱水凝胶微针及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chen et al. | Preparation, properties and challenges of the microneedles-based insulin delivery system | |
CN110917176B (zh) | 一种可植入型缓释微针贴片及其制备方法 | |
US20150141910A1 (en) | Microneedles for therapeutic agent delivery with improved mechanical properties | |
JP5977675B2 (ja) | 皮膚治療用微細針集積型製剤 | |
KR101747099B1 (ko) | 생체적합성 고분자를 이용한 마이크로니들의 제조방법 | |
US8167852B2 (en) | Microneedle device and method for producing the same | |
CN110870846A (zh) | 一种可快速植入型缓释微针贴片及其制备方法 | |
US7731983B2 (en) | Method and composition for the treatment of scars | |
CN114099936A (zh) | 一种长效美容填充和缓释给药用可溶微针及其制备方法 | |
AU2010303414B2 (en) | Methods and compositions for skin regeneration | |
JPWO2014069615A1 (ja) | レチノイン酸マイクロニードル | |
KR101832716B1 (ko) | 정량 투여가 가능하며 약물 투입 속도 조절이 가능한 미세바늘 구조체 및 제조방법 | |
CN112999297A (zh) | 用于瘢痕治疗的微针贴片及其制备方法 | |
CN113827544B (zh) | 一种耐热型可植入式聚合物微针及其制备方法和应用 | |
KR102493997B1 (ko) | 센텔라아시아티카를 함유한 용해성 마이크로니들 패치 | |
CN113908425A (zh) | 一种快速制备微针贴的方法 | |
CN115737782A (zh) | 携载蜂毒肽纳米颗粒和/或抗原的微针贴片、制备方法及应用 | |
KR20160128887A (ko) | 글루타치온 함유 용해성 미세바늘 패치 | |
Alshammari et al. | An update on microneedle in insulin delivery: quality attributes, clinical status and challenges for clinical translation | |
CN110279887B (zh) | 一种多用途光子冷凝胶及其制备方法 | |
Huang et al. | Sustained release microneedles: materials and applications in facial rejuvenation | |
KR20160072627A (ko) | 복합 필러 조성물 | |
KR102610991B1 (ko) | 경피 약물 전달을 위한 마이크로니들 패치 시스템 | |
Kumar et al. | Microneedle for wound healing and dermal application | |
CN115715755A (zh) | 一种祛除黑眼圈的可溶性微针及其制备方法和其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |